PT  - JOURNAL ARTICLE
AU  - Richard G. Moore
AU  - Craig Michael Miller
AU  - Amy K. Brown
AU  - Katina Robison
AU  - Margaret Steinhoff
AU  - Geralyn Lambert-Messerlian
TI  - Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus
AID  - 10.1097/IGC.0b013e3182229ad8
DP  - 2011 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - 1185--1190
VI  - 21
IP  - 7
4099  - http://ijgc.bmj.com/content/21/7/1185.short
4100  - http://ijgc.bmj.com/content/21/7/1185.full
SO  - Int J Gynecol Cancer2011 Oct 01; 21
AB  - Objective: The purpose of this pilot study was to determine whether the biomarker human epididymis protein 4 (HE4) correlates with depth of myometrial invasion, histologic grade, lymph vascular space invasion, positive cytologic washings, and nodal metastases in patients with endometrioid adenocarcinoma of the uterus.Methods: This was a prospective, observational study in women with biopsy-proven endometrioid adenocarcinoma. Concentrations of HE4 were assessed before surgery, and all surgical specimens were reviewed by dedicated gynecologic pathologists.Results: Included were a total of 96 women with endometrioid adenocarcinomas of the uterus, most (77%) with stage I disease. Levels of serum HE4 greater than 70 pM displayed a sensitivity of 94% and a negative predictive value of 97% in identifying stage IA (<50% myometrial invasion) versus stage IB (≥50% myometrial invasion) tumors and a sensitivity of 82% and negative predictive value of 82% versus all more advanced tumors.Conclusions: Human epididymis protein 4 may be a useful marker preoperatively in the clinical decision process for determining the need for lymph node dissection in women with endometrioid endometrial cancer.